Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: First year results of the LIBRA post-registration safety study

Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: First year results of the LIBRA post-registration safety study

Background. Netakimab has shown high efficacy in controlled clinical trials in the treatment of patients with ankylosing spondylitis (AS). This article presents results of an observational study of netakimab using in routine clinical practice.Methods. Patients were recruited for the study from Augus...

Full description

Saved in:
Bibliographic Details
Main Authors: Sh. Erdes, V. I. Mazurov, I. Z. Gaydukova, O. N. Anoshenkova, I. B. Vinogradova, Yu. Yu. Grabovetskaya, S. Yu. Davidian, O. E. Epifanova, N. A. Kiryukhina, L. V. Masneva, I. V. Menshikova, O. N. Mironenko, N. E. Nikulenkova, T. V. Povarova, A. N. Polyatika, R. R. Samigullina, A. E. Sizikov, I. N. Totrov, I. F. Umnova, J. V. Usacheva, A. L. Chudinov
Format: Article
Language:Russian
Published: IMA PRESS LLC 2024-01-01
Series:Научно-практическая ревматология
Subjects:
netakimab
drug retention rate
ankylosing spondylitis
Online Access:https://rsp.mediar-press.net/rsp/article/view/3472
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://rsp.mediar-press.net/rsp/article/view/3472

Similar Items